Table 2.
Patient’s substance use treatment history and time to relapse
| Year | Treatment | Time to relapse for both alcohol and tobacco use |
|---|---|---|
| 2010 | Admitted for inpatient rehabilitationa for 3 months | 2 months after discharge |
| 2013 | Admitted for inpatient rehabilitationb for 3 months | 1 month after discharge |
| 2014 | Admitted for inpatient rehabilitationa for 3 months | 3 months after discharge |
| 2017 | Admitted for inpatient rehabilitationa for 3 months | 4 months after discharge |
| April to July 2019 |
Admitted for inpatient rehabilitationb for 3 months; attended out-patient follow-up for 2 months Received oral naltrexone 50 mg once daily for 5 months. After this, he had a naltrexone implant (765 mg) inserted because oral naltrexone was out of stock. He relapsed a week after the implant was inserted Received nicotine replacement therapy and bupropion 150 mg once daily for tobacco use disorder for 3 months |
2 months after discharge with naltrexone implant in-situ |
| February to August 2021 |
Admitted for inpatient rehabilitationb for 6 months Received naltrexone 50 mg once daily for 6 months Received nicotine replacement therapy for tobacco use disorder for 3 months. He did not receive bupropion because it was out of stock |
2 weeks after in-patient treatment while on oral naltrexone A decision was made to try IV ketamine in light of recent evidence showing efficacy for severe alcohol use disorder |
atreatment was conducted in a residential setting that offers therapy based on alcohol anonymous and peer recovery support strategies
btreatment was conducted in a setting offering medically managed intensive in-patient services